Navigate Fool.com
Will XOMA beat
the market?

XOMA Limited


Community Rating: 2 Stars: Unattractive

4.21 -0.11 (-2.55%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $4.29
Previous Close $4.32
Daily Range $4.19 - $4.42
52-Week Range $3.02 - $9.57
Market Cap $448.7M
P/E Ratio -2.94
Dividend (Yield) $0.00 (0.0%)
Volume 1,054,008
Average Daily Volume 2,540,593
Current FY EPS -$0.66

How do you think XOMA
will perform against the market?

Top XOMA Bull/Bear Pitches


zzlangerhans (< 20)
Submitted April 18, 2011

Did I get the thumb right this time? Hopefully I won't regret it. Xoma's recent failure to demonstrate benefit of 052 in diabetes has set up an interesting situation. As of the end of 2010, the compa … More

0 Replies Reply Report this Post

BrianRuth (< 20)
Submitted March 5, 2007

Calling BS on this one. It would be great if they could help cancer with recombinant whatever, but I think 9 out of 10 microcap companies in this space will go bankrupt.

1 Replies Reply Report this Post

News & Commentary Rss Feed

Want Clinical Trial Success? Look Here

Avoid drugs like XOMA's gevokizumab and look at antivirals and antibiotics like Gilead Sciences' Sovaldi.

Why XOMA Corp. Shares Slumped

Does this analyst make a good case? Or is it just more noise from Wall Street?

This Week in Biotech: Put It in Print

Four clinical updates -- two of them in print -- as well as an FDA approval after seven years are this week's top biotech stories.

Down 30%, Worth a Look

XOMA falls after phase 2 trials fail, but its anti-inflammatory drug gevokizumab still has potential in other diseases.

Why Hovnanian Enterprises, XOMA, and Yongye International Tumbled Today

The stock market finished mostly unchanged amid no new news on the international front, but these stocks suffered substantial losses today. Find out what cause their fall.

3 Stocks Making Massive 1-Day Moves

These three winners and losers in the biotech space today moved big. Really big.

Why XOMA Corp. Shares Zoomed Lower

XOMA shares tumble after it announces a pipeline update regarding its lead experimental drug, gevokizumab.

US Futures Give Up Small Gains, Now Flat After Weak Payrolls Report

Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK

Xoma, Biogen, Agenus, and GSK could all loom large in health care headlines this morning.

US Futures Edge Higher; Private Companies Add Less Jobs Than Expected in February

See More XOMA News...





XOMA Limited (XOMA) Description

A biopharmaceutical company that discovers, develops and manufactures antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer and infectious diseases. Website: http://www.xoma.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks